Adventrx Pharmaceuticals has signed an agreement to acquire SD Pharmaceuticals, a privately held company. The acquisition will be an all-stock exchange, valued at nearly $10 million. As part of the transaction, Adventrx will acquire worldwide intellectual property rights to eight oncology and infectious disease product candidates, including some rights to SDP-012 (ANX-530, vinorelbine emulsion). In October 2005, Adventrx licensed U.S. development and marketing rights to SDP-012 from SD Pharma...